<DOC>
	<DOC>NCT00987844</DOC>
	<brief_summary>Objectives: To evaluate the clinical long-term safety and the tolerability, patient satisfaction, pharmacokinetics and use of pattern of prucalopride given in doses up to 4 mg per day to patients with chronic constipation (CC).</brief_summary>
	<brief_title>Study to Evaluate Long-Term Safety, Tolerability, and Satisfaction With Prucalopride in Chronic Constipation</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<criteria>1. Male and nonpregnant, non breastfeeding female outpatients at least 18 years of age. 2. Patient completed the entire treatment period of one of the following studies: PRUUSA3, PRUUSA11, PRUUSA13, PRUUSA21, PRUUSA25, PRUUSA27 or PRUUSA28, or Patient participated in the retreatment study PRUUSA28 and did not qualify for Treatment period II after both washout periods. 1. Patient with impaired renal function 2. Patient with clinically significant abnormalities of haematology, urinalysis, or blood chemistry. 3. Female of childbearing potential without adequate contraceptive protection during the study. 4. Patient who used an investigation drug other than prucalopride in the 30 days preceding the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>